Tilray's Rescheduling Rally Keeps Fading -- Where Will the Stock Be if Washington Stalls Again?

Tilray shares have fallen from a $23.20 high late last year to just under $5 (near the $3.67 52-week low) despite U.S. medical cannabis rescheduling from Schedule I to Schedule III. In Q4 FY2026, revenue rose 25% YoY to $281.7M, but total growth was modest (just under 3%) and heavily influenced by a $53.7M BrewDog asset acquisition; excluding the acquired $51.1M contribution, beverage revenue declined 17%. The company posted a net loss per share of -$0.43 (better than -$13.01 a year ago) largely due to prior impairment charges, and the article warns that even potential broader rescheduling for adult-use may not translate into attractive economics given continued regulation and competitive pressures.

Analysis

TLRY is still trading more like a policy lottery ticket than an operating business, and that matters because the policy path has asymmetry: incremental reform helps sentiment first, but only a subset of the industry gets real earnings lift. The biggest economic winners from any further easing are U.S.-centric multi-state operators in the MSOS basket and names like CURLF, GTBIF, and TCNNF, where 280E relief would translate into immediate after-tax margin expansion; TLRY’s upside is mostly rerating, not a clean P&L step-up.

Second-order, a broader federal move would likely widen the gap between U.S. operators and Canadian LPs. If investors reprice cannabis as a domestic U.S. cash-flow story, capital should rotate toward firms with plant-touching U.S. EBITDA and away from Canada-heavy assets that still face oversupply, price compression, and limited interstate economics. TLRY’s beverage diversification can soften the downside, but it does not create enough organic growth to offset cannabis weakness if policy momentum stalls.

The contrarian mistake is assuming rescheduling is binary bullish for every cannabis equity. For TLRY, Schedule III is more of a sentiment catalyst than a structural fix unless it is paired with broader adult-use legalization or tax reform; otherwise, the illicit market and state-by-state fragmentation remain intact. The time horizon matters: expect the sharpest move in days on headlines, a drift over 1-3 months as rulemaking slows, and a likely fade over 6-18 months unless revenue excluding acquisitions meaningfully accelerates.

Key Decisions for Investors

• Short TLRY into policy-driven strength or use a 3-6 month put spread; thesis breaks if regulators advance beyond Schedule III toward broader adult-use reform or if organic revenue growth re-accelerates without acquisition help.
• Pair trade: long MSOS, short TLRY for 1-3 months to express the view that U.S. operators capture the real earnings benefit from tax relief while TLRY mostly gets headline beta.
• If a single-name short is too noisy, wait for a bounce above recent resistance and sell call spreads on TLRY; this keeps downside defined if Washington headlines squeeze the stock intraday.
• Set a watch item on DEA/FDA timing and any explicit rejection of interstate-commerce changes; if broader reform is kicked out, add to TLRY shorts on the next rally.